BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA EBITDA Margin
EBITDA as a percentage of revenue.
BioAge Labs, Inc.NASDAQ: BIOA
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -799.1%
EBITDA Margin was -799.1% in Q1 FY2026, up 71.7 pp from a year earlier. On a trailing-twelve-month basis it was -864.8%, up 3922.9 pp year over year.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 9 analysts of -1374.2% for the fiscal year ending Dec 2026, down from -886.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -799.1%+38.5 pp QoQ
- Last fiscal yearDec 2025
- -886.0%— YoY
- LTMMar 2026
- -864.8%+3922.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +71.7 pp | -973.7 pp | -1045.5 pp |
| 1 year | — | -488.2 pp | — |
| 3 years | — | -2942.2 pp | — |
| 5 years | +651.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -886.0%
- Year-over-year change
- —
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -886.0% | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
EBITDA Margin vs competitors
How BIOA compares with its peers on the latest reported figures
- BIOA's LTM Mar 2026 EBITDA Margin of -864.8% is the 6th highest of the 7 companies compared; the peer median is -44.8%.
- Its year-over-year change of +3922.9 pp is the highest of 6, against a peer median of +18.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 3.4% | -11.6 pp | +14.0 pp | |
| LTM Mar 2026 | -0.8% | — | -18.4 pp | |
| LTM Mar 2026 | -23.8% | +18.3 pp | +37.0 pp | |
| LTM Mar 2026 | -65.7% | +112.4 pp | +874.7 pp | |
| LTM Mar 2026 | -258.7% | +387.8 pp | +719.4 pp | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -864.8% | +3922.9 pp | — |
| LTM Mar 2026 | -3956.7% | -3182.9 pp | -1247.4 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding BIOA) | -44.8% | +18.3 pp | +25.5 pp | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 9M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 9M |
| Gross Margin | — | — | — | 100.0% |
| Research & Development | 30.52M | 33.89M | 59.04M | 73.97M |
| Selling, General & Admin | 9.45M | 14.51M | 19.16M | 27.81M |
| Operating Expenses | 39.97M | 48.4M | 78.19M | 101.78M |
| Depreciation & Amortization | 129K | 162K | 167K | 213K |
| EBITDA | (39.35M) | (55.9M) | (68.58M) | (79.7M) |
| EBITDA Margin | — | — | — | -886.0% |
| Operating Income | (39.97M) | (48.4M) | (78.19M) | (92.78M) |
| Operating Margin | — | — | — | -1031.5% |
| Interest Income | 465K | 2.43M | 9.63M | 13.09M |
| Interest Expense | 241K | 7.79M | 2.37M | 697K |
| Other Income / Expenses | 247K | (15.45M) | 7.09M | 12.18M |
| Income Before Tax | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Pre-Tax Margin | — | — | — | -896.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Net Margin | — | — | — | -896.1% |
| EPS (Basic) | (1.16) | (1.87) | (1.98) | (2.24) |
| EPS (Diluted) | (1.16) | (1.87) | (1.98) | (2.24) |
| Weighted Avg Shares | 34.17M | 34.2M | 35.85M | 35.93M |
| Weighted Avg Shares (Diluted) | 34.17M | 34.2M | 35.85M | 35.93M |
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.